Graft rejection across solid organ transplants: mechanisms, monitoring, and immunosuppressive therapeutics.

Abstract

Organ and tissue transplantation has transformed the management of end-stage organ failure, yet graft rejection remains a major barrier. Rejection arises from complex immune mechanisms involving MHC mismatch, T-cell allorecognition, and antibody-mediated injury. Advances in immunosuppressive therapy have improved graft survival, but significant challenges persist. This scoping review synthesizes current insights into the immunological basis of graft rejection and evaluates conventional, biologic, and emerging immunosuppressive strategies. Particular attention is given to organ-specific differences and newer fields such as vascularized composite allografts (VCA) and xenotransplantation. A systematic literature search was conducted across PubMed, Google Scholar, Cochrane, and ClinicalTrials.gov (updated June 2025) following PRISMA guidelines. Studies addressing mechanisms of rejection, therapeutic innovations, and clinical outcomes in solid organ transplantation were included. Rejection manifests in distinct forms: hyperacute rejection, though rare due to modern screening, remains catastrophic when pre-existing antibodies are present; acute rejection affects 10%-20% of patients within the first year, driven by both T-cell and antibody-mediated pathways; and chronic rejection, emerging months to years later, leads to progressive fibrosis, vasculopathy, and graft loss across organs. The degree of HLA mismatch consistently emerged as the strongest predictor of long-term survival. Conventional regimens of corticosteroids, calcineurin inhibitors, and antimetabolites remain foundational but are limited by nephrotoxicity, metabolic complications, and infection risk. Biologics such as basiliximab, belatacept, and rituximab have introduced more targeted suppression, while innovative approaches, including regulatory T-cell therapy, tolerogenic dendritic cells, gene-editing strategies, and nanotechnology-based drug delivery, show promise. Despite these advances, long-term therapy is challenged by 20%-70% patient non-adherence, heightened infection risk, and malignancy. Future strategies must emphasize personalized, biomarker-guided regimens, immune tolerance induction, and AI-driven diagnostics to achieve durable graft acceptance with minimal complications. Integration of consensus frameworks and precision medicine approaches will be essential to improving long-term graft survival and patient health.